BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Vaccines clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for vaccine: 430 (142 sponsors; 105 newly posted in the last 180 days, 9 stopped in the last 180 days; 18 new-entrant sponsors). Momentum score 26.7, rank 8 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 8, Phase 1 100, Phase 2 123, Phase 3 124, Phase 4 24, N/A 51.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Pfizer PFE | 37 | NA 14, P4 1, P3 16, P2 3, P1 3 | 11 | 9 |
| GlaxoSmithKline | 31 | P3 14, P2 8, P1 6, NA 1, P4 2 | 7 | 10 |
| Sinovac Biotech Co., Ltd SVA | 20 | P4 4, P1 2, P3 10, P2 2, NA 2 | 6 | 9 |
| Sanofi SNY | 22 | NA 3, P1 4, P2 5, P4 1, P3 9 | 9 | 5 |
| Merck Sharp & Dohme LLC MRK | 10 | P1 1, P3 8, NA 1 | 1 | 1 |
| CanSino Biologics Inc. | 14 | NA 4, P2 2, P4 1, P1 3, P3 4 | 5 | 2 |
| Changchun BCHT Biotechnology Co. | 12 | P4 2, P1 5, P3 3, EARLY_P1 1, P2 1 | 3 | 2 |
| Sanofi Pasteur, a Sanofi Company SNY | 10 | P2 6, P3 3, NA 1 | 0 | 4 |
| Bavarian Nordic | 7 | P1 1, P2 3, P3 3 | 1 | 2 |
| MAXVAX Biotechnology Limited Liability Company | 7 | P2 2, P3 3, P1 1, NA 1 | 1 | 0 |
| Sinovac Life Sciences Co., Ltd. | 7 | P1 2, P3 3, P2 2 | 1 | 1 |
| PT Bio Farma | 5 | P3 3, P1 1, NA 1 | 3 | 2 |
| Takeda TAK | 5 | NA 2, P3 3 | 0 | 2 |
| Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 4 | P3 3, P1 1 | 0 | 0 |
| ModernaTX, Inc. | 20 | NA 2, P1 7, P4 4, P2 5, P3 2 | 8 | 7 |
| BioNTech SE BNTX | 8 | P2 2, P1 3, P4 1, P3 2 | 3 | 1 |
| Sinovac (Dalian) Vaccine Technology Co., Ltd. | 5 | P4 3, P3 2 | 0 | 0 |
| GC Biopharma Corp | 4 | P2 1, P3 2, P1 1 | 3 | 1 |
| Shanghai Bovax Biotechnology Co., Ltd. | 4 | P3 2, NA 1, P2 1 | 0 | 1 |
| Bharat Biotech International Limited | 3 | P2 1, P3 2 | 0 | 0 |
| Inmunotek S.L. new entrant | 2 | P3 2 | 2 | 0 |
| National Vaccine and Serum Institute, China | 2 | P3 2 | 0 | 0 |
| Guangzhou Patronus Biotech Co., Ltd. | 8 | P1 5, P2 2, P3 1 | 2 | 0 |
| Serum Institute of India Pvt. Ltd. | 6 | NA 2, P1 1, P3 1, P2 2 | 3 | 2 |
| Suzhou Abogen Biosciences Co., Ltd. | 6 | P2 2, P3 1, P1 2, EARLY_P1 1 | 1 | 0 |
New-entrant sponsors: Inmunotek S.L..
Recently stopped trials
- NCT07086222 Novavax - terminated: The study was terminated early due to low COVID-19 incidence and high population immunity, limiting meaningful vaccine efficacy assessment. Efficacy and Safety of NVX-CoV2705
- NCT05589597 Enterome - terminated: Sponsor decision to stop recruitment in context of overall EO4010 development goals. Stop of recruitment was not related to any safety conce EO4010 in Previously Treated Metastatic Colorectal Carcinoma
- NCT06397768 Sanofi Pasteur, a Sanofi Company - terminated: Sponsor decision Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddler
- NCT05876377 Pfizer - terminated: Study discontinued due to questions of data validity and bias in data which would limit causal inference and estimation of vaccine effective Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
- NCT06790966 PDS Biotechnology Corp. - terminated: The study is being discontinued solely based on financial constraints and is not related to the safety of study participants, the investigat Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- NCT05701800 ModernaTX, Inc. - terminated: The clinical study was terminated prior to the start of Phase 2 following a business decision to discontinue further development of the vacc A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
- NCT06705140 Sanofi Pasteur, a Sanofi Company - terminated: Sponsor decision A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in
- NCT04919109 Codagenix, Inc - terminated: Sponsor Decision Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children
- NCT04904549 Sanofi Pasteur, a Sanofi Company - terminated: The study was terminated as per Sponsor decision Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-23 est. | P3 | GlaxoSmithKline | NCT07596199 A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women | Diphtheria-Tetanus-acellular Pertussis Vaccines | active not recruiting | 102 |
| 2026-11-28 est. | P3 | Sanofi SNY | NCT07103148 A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population | Yellow Fever Immunization | active not recruiting | 2440 |
| 2026-12 est. | P1/P2 | Dren Bio | NCT05475925 A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | LGLL - Large Granular Lymphocytic Leukemia; Primary Cutaneous Gamma-Delta T-Cell Lymphoma; Primary C | recruiting | 200 |
| 2026-12-01 est. | P1/P2 | Sanofi SNY | NCT06907511 Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain | Pandemic Influenza Immunization; Healthy Volunteers | active not recruiting | 720 |
| 2027-01 est. | P3 | Sinovac Biotech Co., Ltd SVA | NCT07505836 Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months | Epidemic Meningitis; Meningococcal Vaccines | recruiting | 1040 |
| 2027-01-18 est. | P1/P2 | Sanofi Pasteur, a Sanofi Company SNY | NCT06686654 Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Yea | Human Metapneumovirus Immunization; Respiratory Syncytial Virus Immunization | active not recruiting | 1530 |
| 2027-02 est. | P3 | PT Bio Farma | NCT07854847 Study Interchangeability Hep-B Vaccine Administered at Birth Dose | Vaccination Adverse Event; Immunogenicity, Vaccine | not yet recruiting | 270 |
FDA decision events (last 12 months and upcoming)
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-10-01 | FDA AdCom | held | AdCom 2026-10-01: Vaccines and Related Biological Products Advisory Committee | ||
| 2026-08-05 | PDUFA date (company-disclosed) | date passed | Moderna, Inc. MRNA | PDUFA August 5 - Moderna, Inc. | |
| 2026-06-18 | FDA AdCom | held | AdCom 2026-06-18: Vaccines and Related Biological Products Advisory Committee | ||
| 2026-05-28 | FDA AdCom | held | AdCom 2026-05-28: Vaccines and Related Biological Products Advisory Committee | ||
| 2026-03-12 | FDA AdCom | held | AdCom 2026-03-12: Vaccines and Related Biological Products Advisory Committee |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P3 | Sinovac Biotech Co., Ltd SVA | NCT07505888 Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years | Epidemic Meningitis; Meningococcal Vaccines | active not recruiting | 660 |
| 2026-09-20 est. | P2/P3 | Bharat Biotech International Limited | NCT07555392 A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age. | Active Immunisation for Chikungunya Virus Infection | recruiting | 1000 |
| 2026-09-04 | P3 | GlaxoSmithKline | NCT07596173 A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged | Diphtheria-Tetanus-acellular Pertussis Vaccines | completed | 90 |
| 2026-08-01 est. | P3 | Sinovac (Dalian) Vaccine Technology Co., Ltd. | NCT07473427 Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children | Varicella (Chickenpox); Varicella Immunisation | not yet recruiting | 300 |
| 2026-07-15 est. | P3 | Sinovac (Dalian) Vaccine Technology Co., Ltd. | NCT07475000 Second Dose of Varicella Vaccine in Healthy Children | Varicella (Chickenpox); Varicella Immunisation | recruiting | 300 |
| 2026-07-02 | P3 | Medigen Vaccine Biologics Corp. | NCT07178522 A Study to Evaluate the Immunogenicity and Safety of an EV71 Vaccine (Envacgen®) in Children Aged 6 to <10 Years Compared to Children Aged 2 to <6 Years | Enterovirus 71 Inactivated Vaccine | active not recruiting | 379 |
| 2026-05-31 est. | P1/P2 | Sinovac Biotech Co., Ltd SVA | NCT07400003 Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine | Herpes Zoster; mRNA Vaccine | recruiting | 519 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "vaccine"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.